Impacto de la inmunonutrición en la evolución de los pacientes con esclerosis múltiple mayores de 20 años de edad: revisión narrativa

Autores/as

  • José Guillermo Salcedo-Hurtado 18000681 https://orcid.org/0000-0003-0932-5963
  • Susana Mireya Alvarez-Osorio https://orcid.org/0000-0002-8805-0170
  • Diana Paola Nossa-Martínez https://orcid.org/0000-0002-7695-6741
  • Carmen Cecilia Vergara-Jiménez https://orcid.org/0000-0001-6237-7987

DOI:

https://doi.org/10.35454/rncm.v6n3.522

Palabras clave:

Dieta de inmunonutricion, Esclerosis múltiple, Dieta, Sistema inmunológico, Suplementos dietéticos

Resumen

Introducción: la esclerosis múltiple (EM) es una enfermedad inflamatoria crónica ocasionada por múltiples factores que afectan al sistema nervioso central (SNC), lo que conlleva discapacidades, principalmente, en los adultos jóvenes. La nutrición está dentro de estos factores patogénicos y más recientemente se incluye la disfunción inmunitaria, local y sistémica que produce la EM en la microbiota intestinal (MBI), y afecta órganos como el cerebro. 

Objetivo: en esta revisión narrativa se analizó el impacto de la terapéutica con nutrientes específicos (inmunonutrientes) en los síntomas y la progresión de la enfermedad en pacientes adultos jóvenes con EM. 

Método: se realizó una búsqueda de artículos en las plataformas PubMed y MedLine entre enero de 2012 y diciembre de 2022. 

Resultados: la EM destruye la mielina, lo que produce áreas de desmielinización en la sustancia blanca. Teniendo en cuenta este componente inflamatorio, la investigación muestra que nutrientes específicos como probióticos, ácidos grasos omega-3 (ω-3) y la vitamina D, por sus efectos favorables en la modulación de la inflamación, presentan impactos positivos en los síntomas de estos pacientes; no así para frenar su evolución. 

Conclusiones: el uso de suplementación con inmunonutrientes reporta efectos favorables en paciente con EM. Ante la escasa evidencia sobre el tema, con esta revisión se pretende seguir aportando a la literatura en desarrollo sobre el uso de estos nutrientes en pacientes adultos jóvenes con EM. 

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Susana Mireya Alvarez-Osorio, https://orcid.org/0000-0002-8805-0170

Enfermera. Facultad de enfermería, Universidad Pontificia Bolivariana Medellín, Colombia. Fundación Universitaria Sanmartín.

Diana Paola Nossa-Martínez, https://orcid.org/0000-0002-7695-6741

Médica general. Facultad de Medicina, Universidad de Cartagena (Bolívar), Colombia

Carmen Cecilia Vergara-Jiménez, https://orcid.org/0000-0001-6237-7987

Nutricionista dietista. Facultad de Ciencias, Pontificia Universidad Javeriana. Bogotá, Colombia. Clinica los Cobos.

Citas

Qureshi M, Al-Suhaimi EA, Wahid F, Shehzad O, Shehzad A. Therapeutic potential of curcumin for multiple sclerosis. Neurol Sci. 2018;39(2):207-14. doi: 10.1007/s10072-017-3149-5

Martinez-Altarriba MC, Ramos-Campoy O, Luna-Calcaño IM, Arrieta-Antón E. Revisión de la esclerosis múltiple (2). Diagnóstico y tratamiento [A review of multiple sclerosis (2). Diagnosis and treatment]. Semergen. 2015;41(6):324-8. Spanish. doi: 10.1016/j.semerg.2014.07.011

Shah P. Symptomatic management in multiple sclerosis. Ann Indian Acad Neurol. 2015;18(Suppl 1):S35-42. doi: 10.4103/0972-2327.164827

Fox RJ, Thompson A, Baker D, Baneke P, Brown D, Browne P, et al. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler. 2012;18(11):1534-40. doi: 10.1177/1352458512458169

Storoni M, Plant GT. The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple Sclerosis. Mult Scler Int. 2015;2015:681289. doi: 10.1155/2015/681289

Livingston T, Fay M, Iyer R, Wells W, Pill MW. Quantifying Differences in Health Care Consumption for the Management of Multiple Sclerosis Within Privately and Publicly Insured Health Care Programs. J Manag Care Spec Pharm. 2016;22(12):1385-391. doi: 10.18553/jmcp.2016.22.12.1385

Dos Passos GR, Sato DK, Becker J, Fujihara K. Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications. Mediators Inflamm. 2016;2016:5314541. doi: 10.1155/2016/5314541

Mokry LE, Ross S, Ahmad OS, Forgetta V, Smith GD, Goltzman D, et al. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS Med. 2015;12(8):e1001866. doi: 10.1371/journal.pmed.1001866

Wu H, Zhao M, Yoshimura A, Chang C, Lu Q. Critical Link Between Epigenetics and Transcription Factors in the Induction of Autoimmunity: a Comprehensive Review. Clin Rev Allergy Immunol. 2016;50(3):333-44. doi: 10.1007/s12016-016-8534-y

Pierrot-Deseilligny C, Souberbielle JC. Vitamin D and multiple sclerosis: An update. Mult Scler Relat Disord. 2017;14:35-45. doi: 10.1016/j.msard.2017.03.014

Penesová A, Dean Z, Kollár B, Havranová A, Imrich R, Vlček M, et al. Nutritional intervention as an essential part of multiple sclerosis treatment? Physiol Res. 2018;67(4):521-33. doi: 10.33549/physiolres.933694

Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: A comprehensive review. Neurol Ther. 2018;7(1):59-85. doi: 10.1007/s40120-017-0086-4

Hadgkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, van der Meer DM. Methodology of an International Study of People with Multiple Sclerosis Recruited through Web 2.0 Platforms: Demographics, Lifestyle, and Disease Characteristics. Neurol Res Int. 2013;2013:580596. doi: 10.1155/2013/580596

El Aidy S, Dinan TG, Cryan JF. Immune modulation of the brain-gut-microbe axis. Front Microbiol. 2014;5:146. doi: 10.3389/fmicb.2014.00146

Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016;14(8):e1002533. doi: 10.1371/journal.pbio.1002533

Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26:26191. doi: 10.3402/mehd.v26.26191

Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014;16(7):1024-33. doi: 10.1111/cmi.12308

Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7(1):135. doi: 10.1038/s41392-022-00974-4

Shahi SK, Freedman SN, Mangalam AK. Gut microbiome in multiple sclerosis: The players involved and the roles they play. Gut Microbes. 2017;8(6):607-15. doi: 10.1080/19490976.2017.1349041

Picca A, Fanelli F, Calvani R, Mulè G, Pesce V, Sisto A, et al. Gut Dysbiosis and Muscle Aging: Searching for Novel Targets against Sarcopenia. Mediators Inflamm. 2018;2018:7026198. doi: 10.1155/2018/7026198

Blum HE. The human microbiome. Adv Med Sci. 2017;62(2):414-20. doi: 10.1016/j.advms.2017.04.005

Power SE, O’Toole PW, Stanton C, Ross RP, Fitzgerald GF. Intestinal microbiota, diet and health. Br J Nutr. 2014;111(3):387-402. doi: 10.1017/S0007114513002560.

Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunology. 2016;5(4):e73. doi: 10.1038/cti.2016.17

Chu F, Shi M, Lang Y, Shen D, Jin T, Zhu J, et al. Gut Microbiota in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Current Applications and Future Perspectives. Mediators Inflamm. 2018;2018:8168717. doi: 10.1155/2018/8168717

Calahorra L, Camacho-Toledano C, Serrano-Regal MP, Ortega MC, Clemente D. Regulatory Cells in Multiple Sclerosis: From Blood to Brain. Biomedicines. 2022;10(2):335. doi: 10.3390/biomedicines10020335

Budhram A, Parvathy S, Kremenchutzky M, Silverman M. Breaking down the gut microbiome composition in multiple sclerosis. Mult Scler. 2017;23(5):628-36. doi: 10.1177/1352458516682105

Parashar A, Udayabanu M. Gut microbiota: Implications in Parkinson’s disease. Parkinsonism Relat Disord. 2017;38:1-7. doi: 10.1016/j.parkreldis.2017.02.002

Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545-58. doi: 10.1038/nri3871

Rangachari M, Kerfoot SM, Arbour N, Alvarez JI. Editorial: Lymphocytes in MS and EAE: More Than Just a CD4+ World. Front Immunol. 2017;8:133. doi: 10.3389/fimmu.2017.00133

van Baarlen P, Wells JM, Kleerebezem M. Regulation of intestinal homeostasis and immunity with probiotic lactobacilli. Trends Immunol. 2013;34(5):208-15. doi: 10.1016/j.it.2013.01.005

Antonini M, Lo Conte M, Sorini C, Falcone M. How the Interplay Between the Commensal Microbiota, Gut Barrier Integrity, and Mucosal Immunity Regulates Brain Autoimmunity. Front Immunol. 2019;10:1937. doi: 10.3389/fimmu.2019.01937

Kinashi Y, Hase K. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. Front Immunol. 2021;12:673708. doi: 10.3389/fimmu.2021.673708

Gebrayel P, Nicco C, Al Khodor S, Bilinski J, Caselli E, Comelli EM, et al. Microbiota medicine: towards clinical revolution. J Transl Med. 2022;20(1):111. doi: 10.1186/s12967-022-03296-9

Almeida PP, Tavares-Gomes AL, Stockler-Pinto MB. Relaxing the “second brain”: nutrients and bioactive compounds as a therapeutic and preventive strategy to alleviate oxidative stress in the enteric nervous system. Nutr Rev. 2022;80(11):2206-224. doi: 10.1093/nutrit/nuac030

Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol. 2013;6(1):39-51. doi: 10.1177/1756283X12459294

Pihurov M, Păcularu-Burada B, Cotârleţ M, Vasile MA, Bahrim GE. Novel Insights for Metabiotics Production by Using Artisanal Probiotic Cultures. Microorganisms. 2021;9(11):2184. doi: 10.3390/microorganisms9112184

Durazzo A, Nazhand A, Lucarini M, Atanasov AG, Souto EB, Novellino E, et al. An Updated Overview on Nanonutraceuticals: Focus on Nanoprebiotics and Nanoprobiotics. Int J Mol Sci. 2020;21(7):2285. doi: 10.3390/ijms21072285

Calvo-Barreiro L, Eixarch H, Montalban X, Espejo C. Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis. Autoimmun Rev. 2018;17(2):165-74. doi: 10.1016/j.autrev.2017.11.019

Ojeda J, Ávila A, Vidal PM. Gut Microbiota Interaction with the Central Nervous System throughout Life. J Clin Med. 2021;10(6):1299. doi: 10.3390/jcm10061299

Tankou SK, Regev K, Healy BC, Tjon E, Laghi L, Cox LM, et al. A probiotic modulates the microbiome and immunity in multiple sclerosis. Ann Neurol. 2018;83(6):1147-161. doi: 10.1002/ana.25244

Kouchaki E, Tamtaji OR, Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E, et al. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2017;36(5):1245-249. doi: 10.1016/j.clnu.2016.08.015

Tamtaji OR, Kouchaki E, Salami M, Aghadavod E, Akbari E, Tajabadi-Ebrahimi M, et al. The Effects of Probiotic Supplementation on Gene Expression Related to Inflammation, Insulin, and Lipids in Patients With Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Coll Nutr. 2017;36(8):660-65. doi: 10.1080/07315724.2017.1347074

Rahimlou M, Hosseini SA, Majdinasab N, Haghighizadeh MH, Husain D. Effects of long-term administration of Multi-Strain Probiotic on circulating levels of BDNF, NGF, IL-6 and mental health in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Nutr Neurosci. 2022;25(2):411-22. doi: 10.1080/1028415X.2020.1758887

Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492-506. doi: 10.1038/s41422-020-0332-7

Dopkins N, Nagarkatti PS, Nagarkatti M. The role of gut microbiome and associated metabolome in the regulation of neuroinflammation in multiple sclerosis and its implications in attenuating chronic inflammation in other inflammatory and autoimmune disorders. Immunology. 2018;154(2):178-85. doi: 10.1111/imm.12903

Munger K, Åivo J, Hongell K, Soilu-Hänninen M, Surcel H, Ascherio A. Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish maternity cohort. JAMA Neurol. 2016;73(5):515. doi: 10.1001/jamaneurol.2015.4800

Wacker M, Holick M. Vitamin D—effects on skeletal and extraskeletal health and the need for supplementation. Nutrients. 2013;5(1):111-48. doi: 10.3390/nu5010111

Jelinek GA, Marck CH, Weiland TJ, Pereira N, van der Meer DM, Hadgkiss EJ. Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis. BMC Neurol. 2015;15:132. doi: 10.1186/s12883-015-0394-1

Hossein-nezhad A, Holick MF. Vitamin D for health: a global perspective. Mayo Clin Proc. 2013;88(7):720-55. doi: 10.1016/j.mayocp.2013.05.011

Charoenngam N, Holick MF. Immunologic Effects of Vitamin D on Human Health and Disease. Nutrients. 2020;12(7):2097. doi: 10.3390/nu12072097

Feng X, Wang Z, Howlett-Prieto Q, Einhorn N, Causevic S, Reder AT. Vitamin D enhances responses to interferon-β in MS. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e622. doi: 10.1212/NXI.0000000000000622

Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306-14. doi: 10.1001/jamaneurol.2013.5993

Hanaei S, Sahraian MA, Mohammadifar M, Ramagopalan SV, Ghajarzadeh M. Effect of Vitamin D Supplements on Relapse Rate and Expanded Disability Status Scale (EDSS) in Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis. Int J Prev Med. 2021;12:42. doi: 10.4103/ijpvm.IJPVM_208_20

Tredinnik AR, Probst YC. Evaluating the Effects of Dietary Interventions on Disease Progression and Symptoms of Adults with Multiple Sclerosis: An Umbrella Review. Adv Nutr. 2020;11(6):1603-615. doi: 10.1093/advances/nmaa063

Kouchaki E, Afarini M, Abolhassani J, Mirhosseini N, Bahmani F, Masoud SA, et al. High-dose ω-3 Fatty Acid Plus Vitamin D3 Supplementation Affects Clinical Symptoms and Metabolic Status of Patients with Multiple Sclerosis: A Randomized Controlled Clinical Trial. J Nutr. 2018;148(8):1380-386. doi: 10.1093/jn/nxy116. Retraction in: J Nutr. 2021;151(5):1362.

Black LJ, Zhao Y, Peng YC, Sherriff JL, Lucas RM, van der Mei I, et al. Higher fish consumption and lower risk of central nervous system demyelination. Eur J Clin Nutr. 2020;74(5):818-24. doi: 10.1038/s41430-019-0476-z

Pommerich UM, Brincks J, Christensen ME. Is there an effect of dietary intake on MS-related fatigue? - A systematic literature review. Mult Scler Relat Disord. 2018;25:282-91. doi: 10.1016/j.msard.2018.08.017

Zostawa J, Adamczyk J, Sowa P, Adamczyk-Sowa M. The influence of sodium on pathophysiology of multiple sclerosis. Neurol Sci. 2017;38(3):389-98. doi: 10.1007/s10072-016-2802-8

Hucke S, Wiendl H, Klotz L. Implications of dietary salt intake for multiple sclerosis pathogenesis. Mult Scler. 2016;22(2):133-9. doi: 10.1177/1352458515609431

Jörg S, Grohme DA, Erzler M, Binsfeld M, Haghikia A, Müller DN, et al. Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cell Mol Life Sci. 2016;73(24):4611-622. doi: 10.1007/s00018-016-2311-1

Colpitts SL, Kasper EJ, Keever A, Liljenberg C, Kirby T, Magori K, et al. A bidirectional association between the gut microbiota and CNS disease in a biphasic murine model of multiple sclerosis. Gut Microbes. 2017;8(6):561-73. doi: 10.1080/19490976.2017.1353843

Sato W, Yamamura T. Multiple sclerosis: Possibility of a gut environment-induced disease. Neurochem Int. 2019;130:104475. doi: 10.1016/j.neuint.2019.104475

Jangi S, Gandhi R, Cox LM, Li N, Von Glehn F, Yan R, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat. Commun. 2016;7:12015. doi: 10.1038/ncomms12015

Horton MK, McCauley K, Fadrosh D, Fujimura K, Graves J, Ness J, et al. Gut microbiome is associated with multiple sclerosis activity in children. Ann Clin Transl Neurol. 2021;8(9):1867-883. doi: 10.1002/acn3.51441

Varela-Trinidad GU, Domínguez-Díaz C, Solórzano-Castanedo K, Íñiguez-Gutiérrez L, Hernández-Flores TJ, Fafutis-Morris M. Probiotics: Protecting Our Health from the Gut. Microorganisms. 2022;10(7):1428. doi: 10.3390/microorganisms10071428

Bagur MJ, Murcia MA, Jiménez-Monreal AM, Tur JA, Bibiloni MM, Alonso GL, et al. Influence of Diet in Multiple Sclerosis: A Systematic Review. Adv Nutr. 2017;8(3):463-72. doi: 10.3945/an.116.014191

Cantorna MT, Zhao J, Yang L. Vitamin D, invariant natural killer T-cells and experimental autoimmune disease. Proc Nutr Soc. 2012;71(1):62-6. doi: 10.1017/S0029665111003193

Skrobot A, Demkow U, Wachowska M. Immunomodulatory Role of Vitamin D: A Review. Adv Exp Med Biol. 2018;1108:13-23. doi: 10.1007/5584_2018_246

Fatima M, Lamis A, Siddiqui SW, Ashok T, Patni N, Fadiora OE. Therapeutic Role of Vitamin D in Multiple Sclerosis: An Essentially Contested Concept. Cureus. 2022;14(6):e26186. doi: 10.7759/cureus.26186

McLaughlin L, Clarke L, Khalilidehkordi E, Butzkueven H, Taylor B, Broadley SA. Vitamin D for the treatment of multiple sclerosis: a meta-analysis. J Neurol. 2018;265(12):2893-905. doi: 10.1007/s00415-018-9074-6

Jelinek GA, Hadgkiss EJ, Weiland TJ, Pereira NG, Marck CH, van der Meer DM. Association of fish consumption and Ω 3 supplementation with quality of life, disability and disease activity in an international cohort of people with multiple sclerosis. Int J Neurosci. 2013;123(11):792-800. doi: 10.3109/00207454.2013.803104

Mische LJ, Mowry EM. The Evidence for Dietary Interventions and Nutritional Supplements as Treatment Options in Multiple Sclerosis: a Review. Curr Treat Options Neurol. 2018;20(4):8. doi: 10.1007/s11940-018-0494-5

Crabtree-Hartman E. Advanced Symptom Management in Multiple Sclerosis. Neurol Clin. 2018;36(1):197-18. doi: 10.1016/j.ncl.2017.08.015

Altowaijri G, Fryman A, Yadav V. Dietary Interventions and Multiple Sclerosis. Curr Neurol Neurosci Rep. 2017;17(3):28. doi: 10.1007/s11910-017-0732-3

Claflin SB, van der Mei IAF, Taylor BV. Complementary and alternative treatments of multiple sclerosis: a review of the evidence from 2001 to 2016. J Neurol Neurosurg Psychiatry. 2018;89(1):34-41. doi: 10.1136/jnnp-2016-314490

Publicado

2023-08-28

Cómo citar

Salcedo-Hurtado, J. G., Alvarez-Osorio, S. M. ., Nossa-Martínez, D. P. . ., & Vergara-Jiménez, C. C. . (2023). Impacto de la inmunonutrición en la evolución de los pacientes con esclerosis múltiple mayores de 20 años de edad: revisión narrativa. Revista De Nutrición Clínica Y Metabolismo, 6(3), 33–43. https://doi.org/10.35454/rncm.v6n3.522